I think he means process wise and how this Playa out, not the actual results from the trials.
As mentioned about a few times CUV and PAR are the only other re purposed drugs out on the ASX so you can see how they evolved as a comparison for IXC.
The best part of IXC is though that there is no other drug in our market so any sort of positive benefits for patients would make it efficient. They are already very confident that the benefits will show through from this trial and will be progressing to our final trial before getting a drug to market.
IXC Price at posting:
94.0¢ Sentiment: Buy Disclosure: Held
